BioSpace News Archive

Leading technology consultancy for the healthcare industry updates name and appoints award-winning industry executive to leadership role.

The American Society of Hematology announced the institutions that have been selected for the ASH Hematology-Focused Fellowship Training Program, an innovative initiative to address the critical need to expand the hematology workforce.

Embr Labs, a leader in women’s menopausal hot flash management, announced today the poster presentation of landmark study results at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Bluestar Genomics, Inc., today announced it has received Clinical Laboratory Improvement Amendments (CLIA) certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services.

SCIEX, a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches Zeno SWATH DIA, a significant step forward in biomarker discovery and translation workflows.

RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Jefferies 2022 Global Healthcare Conference.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), today presented a trial-in-progress poster describing the study outline of its Phase 1b clinical trial of PH-762, a self-delivering RNAi targeting PD-1, for the treatment of advanced melanoma at the 2022 American Society of Clinical Oncology (ASCO) annual meeting.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to thirteen new employees with a grant date of June 1, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Vincerx Pharma, Inc. announced an update to its strategic priorities and the streamlining and realignment of resources to support its key value-generating indications and programs and extend its estimated cash runway into late 2024.

Lipocine Inc., a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented “LPCN 2101: An Endogenous Neuroactive Steroid for Epilepsy” at the 2022 Epilepsy Foundation Pipeline Conference.